RAS–PI3Kα signaling regulates KrasG12D-induced lymphangiogenesis in complex lymphatic anomalies
Disease Models & Mechanisms · 01.08.2026 · 19 (8)
DOI: 10.1242/dmm.052932 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease Models & Mechanisms, online erschienen am 27.08.2026. Verfasst von Lorenzo M Fernandes und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, TX 75390, USA. Hauptthemen laut MEDLINE: Lymphangiogenesis, Signal Transduction, Proto-Oncogene Proteins p21(ras), Lymphatic Abnormalities. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, U.S. Department of Defense, University of Texas Southwestern Medical Center.
Abstract (Originalsprache)
Complex lymphatic anomalies (CLAs) are rare diseases characterized by the abnormal development of lymphatic vessels. CLAs can be caused by somatic activating variants in KRAS (e.g. KRASG12D), which stimulate MAPK and PI3K signaling. Although KRAS–MAPK signaling is known to play a critical role in CLA pathogenesis, the contribution of KRAS–PI3Kα signaling remains unclear. To investigate the role of RAS activation of PI3Kα in CLAs, we analyzed mice carrying two missense mutations in the RAS-binding domain of p110α (encoded by Pik3ca), the catalytic subunit of PI3Kα. These two mutations block the interaction between p110α and RAS but do not affect its kinase activity. Disruption of RAS-mediated PI3Kα activation in lymphatic endothelial cells reduced lymphatic vessel branching but did not affect lymphatic valve formation. In KrasG12D-mutant mice, blocking RAS activation of p110α reduced the pathological enlargement of lymphatic vessels, but failed to prevent KrasG12D-induced lymphatic valve loss. Similar results were observed following p110α deletion in KrasG12D-mutant mice. Together, these findings demonstrate that KrasG12D drives distinct disease phenotypes through separate downstream pathways. KRAS–PI3Kα signaling promotes pathological lymphatic vessel enlargement, whereas KRAS–MAPK signaling disrupts lymphatic valve formation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, TX 75390, USA.
- Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.
- Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA.
ORCID-Profile: Michael T Dellinger
Förderung
- NHLBI NIH HHS
- U.S. Department of Defense
- University of Texas Southwestern Medical Center
- National Heart, Lung, and Blood Institute
Zitieren
APA
Fernandes, L. M., Tresemer, J., Vallejo, A., Yao, A., Scallan, J. P., & Dellinger, M. T. (2026). RAS–PI3Kα signaling regulates KrasG12D-induced lymphangiogenesis in complex lymphatic anomalies. Disease Models & Mechanisms, 19(8). https://doi.org/10.1242/dmm.052932
Vancouver
Fernandes LM, Tresemer J, Vallejo A, Yao A, Scallan JP, Dellinger MT. RAS–PI3Kα signaling regulates KrasG12D-induced lymphangiogenesis in complex lymphatic anomalies. Disease Models & Mechanisms. 2026;19(8). doi:10.1242/dmm.052932
BibTeX
@article{Fernandes2026,
author = {Fernandes, Lorenzo M and Tresemer, Jeffrey and Vallejo, Angelica and Yao, Alice and Scallan, Joshua P and Dellinger, Michael T},
title = {RAS–PI3Kα signaling regulates KrasG12D-induced lymphangiogenesis in complex lymphatic anomalies},
journal = {Disease Models & Mechanisms},
year = {2026},
volume = {19},
number = {8},
doi = {10.1242/dmm.052932}
}
EUVIMED